Skip to main content
. 2004 Apr 30;32(8):2396–2410. doi: 10.1093/nar/gkh527

Figure 6.

Figure 6

Inhibition of c-myc promoter activity by daunomycin-conjugated TFO in prostate and breast cancer cells. Cells were transfected for 6 h either with p1388-Myc or p262-Myc reporter plasmid, a pRL control plasmid and the indicated concentrations of dauno-GT11 (empty bars) or dauno-CO11 (filled bars). Luciferase activity was measured after 24 h. Data are presented as percent of luciferase activity in TFO-treated cells compared to cells incubated with an equal concentration of control oligonucleotide. (A) DU145 cells transfected with p1388-Myc; (B) DU145 cells transfected with p262-Myc; (C) MCF-7 cells transfected with p262-Myc; (D) MDA-MB-231 cells transfected with p262-Myc.